Benjamin N.R. Cheyette, M.D, Ph.D.


Professor Emeritus, UCSF Director of ADHD Program, Mindful Health Solutions

<u>Disclosures</u>

Advisory Board (Equity Compensation), iFocus Health (Reading Tracking)
Advisory Board (Equity Compensation), NEUROSYNC (Eye Tracking)
Expert Consortium (Non-paid), QB Tech


Approximate Prevalence & Co-morbidity of 3 most common psychiatric diagnoses in US adults

Recent epidemiological data:



Lifetime:

(including childhood)




The prevalence of ADHD among <u>Adult Psychiatric Outpatients</u> is even higher than in the general population (and has been steadily climbing)

This accords closely with our experience at

Mindful Health Solutions

Distribution of patients in our practice by primary diagnosis (n ~ 26,500; 98.7% Adult)



The HII-5

A Simple and Rapid Symptom Tracking & Treatment Response Measure for ADHD

At Mindful Health Solutions our clinical culture is built around "Measurement-Based Care"

We use simple quantitative patient self-survey measures to track treatment progress at every visit:

PHQ-9 for Depression GAD-7 for Anxiety and for ADHD.....

Here is a list of all ADHD Self-Survey Measures validated for the purpose of symptom tracking:

1. AAQoL - assesses functioning over the past 2 weeks

29 questions

5 possible answers per question

Good luck getting patients to fill it out at each visit! (too complex)

Brod M, Qual Life Res. 2006 Feb;15(1):117-29.

2. There is no "2"

Some clinicians (and pharma companies) use the ASRS

The first 6 questions can be used in isolation

The ASRS asks about the **last 6 months** of symptoms.

It was designed and validated as a diagnostic screening tool.

It was not designed nor validated to track ADHD over shorter periods of time.



HYPERACTIVITY, IMPULSIVITY, INATTENTION SYMPTOM RATING SCALE

Over the last week how often have you been bothered by the following challenges?

	Not at all	Several Days	More than half the days	Nearly every day
Fidgeting or difficulty sitting still	0	1	2	3
Interrupting other people or acting impulsively	0	1	2	3
Procrastinating on starting tasks	0	1	2	3
Starting but not finishing tasks	0	1	2	3
Mind wandering or forgetting what you were doing or saying	0	1	2	3

____+___+___+

= Total Score: _____

Recommended Scoring Matrix

- 0-2 none/minimal
- 3-5 mild
- 6-8 moderate
- 9-11 moderately severe
- 12**-**15 severe

Hyperactivity, Impulsivity, Inattention Symptom Rating Scale HII-5

<u>Additional Questions (not scored)</u>


If you checked off any challenges, how difficult have they made it for you to do your work, take care of things at home, or get along with other people?

Not difficult at all	Somewhat difficult	Very difficult	Extremely difficult
(managing well)			(debilitating)


Over the last week, I have taken ADHD medications (choose one):

- Every day
- On each day I needed them (but not 7 days/week)
- Intermittently (I forgot on some days when I should have taken them)
- Not at all

The HII-5 initiative – basic numbers (as of 10/10/23)



- 227 unique patients
- **91** with at least 1 repeat HII-5
- Age range: 20-74 (average = 40)
- 57% female; 43% male
- provider participation: 11




The HII-5 initiative – patient vignette

38 y o M, married engineering manager. Supervisor has told him: "You need to work on active listening skills." 5 y o son "bounces off the walls all day" & patient's mother says: "You were exactly the same way." Paternal Grandfather - alcoholic; Father - alcoholic + attentional issues. Pt has no other psychiatric concerns.

ADHD Test Battery Results Summary

WURS: 54 (+) CAARS: ADHD Index: 63 (91%) Inattention Subscales: 77/78 (>99%) CAARS-O (-) QB Inattention: 2.4 (>>99%); Activity 2.9 (>>99%)




The HII-5 initiative – patient vignette

24 y o F, new elementary school teacher, childhood attentional & hyperactivity challenges but never diagnosed. Recently diagnosed elsewhere with ADHD and prescribed atomoxetine: "Working well, no side effects"

ADHD Test Battery Results Summary

WURS: invalid CAARS ADHD Index: 74 (99%) CAARS-O: 80 (>99%) QB Inattention: 2.4 (>>99%); Activity 2.9 (>>99%)




The HII-5 initiative – patient vignette

29 y o F in Tech finance. Depression, anxiety, mood lability since middle school. First treatment age 18 for "road rage" Prior to seeing me prescribed only SSRIs, SNRIs, Bupropion (pooped out)

ADHD Test Battery Results Summary

WURS: 39 (-) CAARS ADHD Index: 72 (99th %ile) CAARS-O: 51 (-) QB Inattention: 1.0 (83 %ile) Activity: 1.8 (96 %ile)




Stable Medications
SNRI (venlafaxine 112.5 mg/day)
augmentation (aripiprazole 1 mg/day)
Stimulant for ADHD varies as shown below

The HII-5 initiative – combined use with PHQ-9 & GAD-7

Reduction in PHQ-9 and GAD-7 in patients successfully treated for ADHD

(HII-5 reduction of 3 or more at follow-up; n = 30)



HII-5 – correlation with WURS, CAARS, QB Test/CPT-3

Work in Progress

HII-5 in pharmacologically-untreated patients who also completed the MHS ADHD Test Battery

(Very) Provisional Conclusions

- Severity on HII-5 correlates with previously-validated Self-Survey Report Scales
 - WURS
 - CAARS ADHD Index
- Correlation with various measures on Continuous Performance Tests (QB, CPT3) less clear so far

...we're working on this.